비교리스트

 카트 문의
시장보고서
상품코드
1511799

골관절염용 주사제 시장 규모, 점유율, 동향 분석 리포트 : 주사제 유형별, 해부학별, 최종 용도별 및 부문별 예측(2024-2030년)

Osteoarthritis Injectables Market Size, Share & Trends Analysis Report By Injection Type (Hyaluronic Acid Injections, Corticosteroids Injections), By Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), By End-use, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 137 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

골관절염용 주사제 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 골관절염용 주사제 시장 규모는 2024-2030년 6.82%의 CAGR을 보이며, 2030년에는 114억 2,000만 달러에 달할 것으로 예측되고 있습니다. 이 시장은 몇 가지 중요한 요인의 영향을 받아 성장하고 있으며, 2021년 1월 Arthritis-health의 데이터에 따르면 50-60세 여성은 호르몬 변화와 근골격계 차이로 인해 남성에 비해 손과 무릎의 골관절염(OA)이 발생하기 쉽습니다. 발생하기 쉽습니다. 또한 미국 국립보건원에 따르면 여성의 비만율이 더 높으며, 이는 위험을 더욱 높인다고 합니다. 미국에서만 2040년까지 골관절염 환자 수는 7,000만 명에 달할 것으로 예측됩니다.

노인 인구 증가는 시장 확대의 주요 요인으로, 2023년 5월 NCBI가 발표한 보고서에 따르면 고령화와 비만의 결합으로 2030년까지 골관절염 환자 수가 2배 이상 증가한 6,700만 명에 달할 것으로 예상되며, 2024년 3월 CDC의 지원을 받은 OAAA의 연구에 따르면 현재 골관절염 환자의 45%가 65세 이상 연령층에 해당하며, 대부분의 환자가 65세 이상에서 발생할 것으로 예상됩니다. 이러한 인구 통계학적 변화는 생산성에 영향을 미치고 작업 효율을 떨어뜨리고 질병 부담을 증가시킬 것입니다.

연구개발 활동도 골관절염 주사제 시장의 성장을 가속하고 있으며, 제약회사와 연구기관은 OA 관리를 위한 신약 개발에 집중하고 있습니다. 바이오세닉이 2024년 1월 발표한 무릎 OA 혁신 치료제 JTA-004의 3상 임상 3상 발표는 치료 옵션 확대에 대한 업계의 노력을 보여줍니다. 학계 연구기관들도 새로운 치료법 개발에 적극 나서고 있습니다. 예를 들어 2023년 3월에 보고된 GP130의 임상시험 약물은 염증과 통증 관리에 유망합니다. 또한 코오롱티슈진의 고관절 OA에 대한 TG-C의 2상 임상시험은 통증과 삶의 질 개선을 평가하는 것을 목표로 하고 있습니다.

OA 치료를 위한 경구용 약물, 수술, 진에 절인 건포도나 구리 팔찌 착용과 같은 가정 요법의 채택은 시장 성장에 부정적인 영향을 미칠 것으로 예상됩니다. 진통제, 비스테로이드성 소염진통제(NSAIDs), 코르티코스테로이드와 같은 경구 및 국소 치료제의 채택은 환자 중심의 접근 방식과 사용 편의성으로 인해 증가하고 있습니다. 또한 OA로 인한 염증과 통증을 관리하기 위한 새로운 경구용 약물을 개발하기 위한 연구 활동 증가는 향후 몇 년간 OA 주사제 시장의 성장을 저해할 것으로 예상됩니다. 예를 들어 2022년 2월 Medivir AB는 MIV-711의 무작위 2a상 임상시험의 사후 분석과 OA 통증 관리에 대한 증상 및 구조적 이점에 대한 사후 분석을 발표했으며, MIV-711은 골 흡수와 연골 분해를 모두 표적으로 하는 경구용 약물입니다.

골관절염 주사제 시장 보고서 하이라이트:

  • 히알루론산(HA) 주사는 OA에서 높은 처방률로 인해 2023년 시장을 장악했습니다.
  • 2023년 무릎 골관절염 분야가 시장을 주도할 것으로 예상됩니다. 무릎 골관절염은 특히 노년층에서 많이 발생하는 질환으로, 미국에서는 50세 이상 남성의 사망 원인 중 두 번째로 높은 비중을 차지합니다.
  • 2023년 병원 약국 부문이 시장을 장악할 것으로 예상 병원 약국은 골관절염 관리에 있으며, 매우 중요한 역할을 하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 세계의 골관절염용 주사제 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 모시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 촉진요인 분석
    • 시장 억제요인 분석
  • 세계의 골관절염용 주사제 시장 분석 툴
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석
    • 가격 분석

제4장 세계의 골관절염용 주사제 시장 : 주사제 유형 추정·동향 분석

  • 주사 유형의 시장 점유율, 2023년과 2030년
  • 부문 대시보드
  • 주사제 유형별 세계 골관절염용 주사제 시장의 전망
  • 2018-2030년 시장 규모와 예측 및 동향 분석

제5장 세계의 골관절염용 주사제 시장 : 해부학적 추정·동향 분석

  • 해부학의 시장 점유율, 2023년과 2030년
  • 부문 대시보드
  • 해부학적 전망에 의한 세계의 골관절염용 주사제 시장
  • 2018-2030년 시장 규모와 예측 및 동향 분석

제6장 세계의 골관절염용 주사제 시장 : 최종 용도 추정·동향 분석

  • 최종 용도 시장 점유율, 2023년 및 2030년
  • 부문 대시보드
  • 최종 용도별 세계 골관절염용 주사제 시장 전망
  • 2018-2030년 시장 규모와 예측 및 동향 분석

제7장 세계의 골관절염용 주사제 시장 : 지역 추정·동향 분석

  • 지역 시장 대시보드
  • 시장 규모, 예측 동향 분석, 2018-2030년 :
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제8장 경쟁 구도

  • 주요 시장 참여 기업별 최근 동향과 영향 분석
  • 기업/경쟁의 분류
  • 벤더 구도
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Anika Therapeutics, Inc.
    • Bioventus.
    • Ferring Pharmaceuticals Inc.
    • Sanofi SA
    • Flexion Therapeutics, Inc.
    • Zimmer Biomet
    • Arthrex, Inc.
    • Royal Biologics
    • Teva Pharmaceutical Industries Ltd.

제9장 결론과 애널리스트의 시점

KSA 24.07.16

Osteoarthritis Injectables Market Growth & Trends:

The global osteoarthritis injectables market size is anticipated to reach USD 11.42 billion by 2030, exhibiting a CAGR of 6.82% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing growth, influenced by several key factors. Women aged 50 to 60 are more susceptible to developing hand and knee osteoarthritis (OA) compared to men, due to hormonal changes and musculoskeletal differences, as highlighted by Arthritis-health data from January 2021. Additionally, obesity rates, higher among women according to the National Institutes of Health, further increase the risk. In the U.S. alone, it is projected that the number of osteoarthritis patients will reach 70 million by 2040.

The growing geriatric population is a significant driver for market expansion. An NCBI report from May 2023 predicts that the combination of an aging population and obesity will more than double the number of osteoarthritis patients to 67 million by 2030. The majority of cases are expected to occur in individuals aged 65 and above, with 45% of current osteoarthritis patients falling into this age group, according to an OAAA study supported by the CDC in March 2024. This demographic shift impacts productivity, reducing work efficiency and increasing the disease burden.

Research and development activities are also boosting the osteoarthritis injectables market growth, with pharmaceutical companies and research institutes focusing on the development of novel drugs for OA management. BioSenic's announcement in January 2024 regarding the phase 3 study of JTA-004, an innovative treatment for knee OA, demonstrates the industry's commitment to advancing treatment options. Academic and research institutes are also actively involved in developing novel therapies. For instance, a GP130 investigational drug, reported in March 2023, shows promise in managing inflammation and pain. Additionally, Kolon TissueGene, Inc.'s Phase 2 clinical trial for TG-C in hip OA aims to evaluate pain and quality-of-life improvements.

The adoption of oral drugs, surgery, and home remedies such as gin-soaked raisins or wearing copper bracelets for the treatment of OA is expected to adversely affect market growth. The adoption of oral and topical treatment drugs such as analgesics, NSAIDs, and corticosteroids, is increasing due to the patient-centric approach and ease of use. Moreover, increase in research activities to develop novel oral drugs to manage inflammation and pain due to OA is anticipated to hinder the market expansion of OA injectable drugs in the coming years. For instance, in February 2022, Medivir AB published the post-hoc analysis of a randomized phase 2a clinical trial of MIV-711 and its symptomatic and structural benefits for pain management of OA. MIV-711 is an orally administered drug targeting both bone resorption and cartilage degradation.

Osteoarthritis Injectables Market Report Highlights:

  • Hyaluronic Acid (HA) injections segment dominated the market in 2023, owing to its high prescription rate in OA.
  • Knee osteoarthritis segment dominated the market in 2023. Knee OA is a prevalent condition particularly affecting older individuals, with the U.S. witnessing it as the second leading cause of incapacity among men aged 50 years and above.
  • Hospital pharmacies segment dominated the market in 2023. Hospital pharmacies play a pivotal role in osteoarthritis management, owing to factors such as higher number of treatments performed in the hospital setting.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Injection Type
    • 1.2.2. End-use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Injection Type
    • 2.2.2. End-use
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Global Osteoarthritis Injectables Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of osteoarthritis
      • 3.2.1.2. Growing geriatric population susceptible to osteoarthritis
      • 3.2.1.3. Increase in R&D activities for injectable drug development
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Adoption of other treatment options
      • 3.2.2.2. High cost of treatment
  • 3.3. Global Osteoarthritis Injectables Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Pricing Analysis
    • 3.3.3. Pricing Analysis

Chapter 4. Global Osteoarthritis Injectables Market: Injection Type Estimates & Trend Analysis

  • 4.1. Injection Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Osteoarthritis Injectables Market by Injection Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Hyaluronic Acid Injections
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Corticosteroid Injections
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Platelet-rich Plasma (PRP) Injections
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Placental Tissue Matrix (PTM) Injections
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Acetylsalicylic Acid (ASA) Injections
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Global Osteoarthritis Injectables Market: Anatomy Estimates & Trend Analysis

  • 5.1. Anatomy Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Osteoarthritis Injectables Market by Anatomy Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Knee Osteoarthritis
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Hip Osteoarthritis
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Hand Osteoarthritis
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Global Osteoarthritis Injectables Market: End-use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Osteoarthritis Injectables Market by End-use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospital Pharmacies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Retail Pharmacies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Global Osteoarthritis Injectables Market: Regional Estimates & Trend Analysis by

  • 7.1. Regional Market Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Anika Therapeutics, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Injection Type benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Bioventus.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Injection Type benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Ferring Pharmaceuticals Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Injection Type benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Sanofi S.A.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Injection Type benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Flexion Therapeutics, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Injection Type benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Zimmer Biomet
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Injection Type benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Arthrex, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Injection Type benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Royal Biologics
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Injection Type benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Teva Pharmaceutical Industries Ltd.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Injection Type benchmarking
      • 8.3.12.4. Strategic initiatives

Chapter 9. Conclusion and Analyst Perspective

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제